Feb. 9, 2022, BEIJING & SHANGHAI & CAMBRIDGE, Mass. – EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, and Neukio Biotherapeutics, a biotechnology company focused on the development and commercialization of allogenic iPSC-CAR-NK cell therapies, today announced an R&D collaboration to develop next-generation immune cell therapies. [Read more…]
Exopharm Signs Master Collaborative Agreement to Manufacture Exosomes for Astellas
-
Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company
-
Initial services will seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm’s facilities in Melbourne followed by the Astellas facilities in Massachusetts USA
-
Future potential collaboration is anticipated following validation
-
This is Exopharm’s first collaboration services agreement with a major pharmaceutical company
StemCyte Reports Successful Phase I Trial Using Cord Blood to Treat Cerebral Stroke
StemCyte Announces Successful Outcome in Phase I Clinical Trial for Treating Acute Cerebral Stroke Using Allogeneic Human Umbilical Cord Blood
StemCyte is a portfolio company of Microbio Group focusing on new drug discovery in cell therapy with operations in the U.S., Taiwan, and India
BALDWIN PARK, Calif., Jan. 26, 2022 — Southern California cord blood therapeutics company StemCyte Inc. is announcing successful preliminary results for Phase I of the company’s clinical trial for treating acute cerebral stroke using monocytes from allogeneic human umbilical cord blood (hUCB). [Read more…]
Excellos Launches as Latest Cell and Gene Therapy CDMO with $15M in Funding
Founded by an Experienced Management Team and Built on the Reach and Infrastructure of the San Diego Blood Bank
SAN DIEGO, January 25, 2022 — Excellos, Incorporated, a cell therapy Contract Development and Manufacturing Organization (CDMO), announces its official corporate launch and closing of $15M in growth funding from Telegraph Hill Partners (THP). Built on the foundation of the San Diego Blood Bank (SDBB), Excellos is focused on supplying cGMP cellular products and services, together with process development and manufacturing expertise to scientists and clinicians working with cell and gene therapies. [Read more…]
Cytiva and Nucleus Biologics join forces to accelerate development of custom cell media for cell and gene therapies
Collaboration will enable transparent, cGMP, and scalable manufacture of custom cell culture media
SAN DIEGO, California, Jan 20, 2022 – Cytiva, a global life sciences leader, and Nucleus Biologics, LLC, The Cell Performance Company™, have signed a collaboration agreement on custom media formulation and fulfillment solutions for the cell and gene therapy industry. Utilizing Nucleus Biologics’ proprietary platform, Cytiva customers will have access to XURI Media AI Guide, an artificial intelligence platform for optimizing cell culture formulations, and XURI Media Designer System, a cell media configurator that enables customization of cell culture media while maintaining formulation ownership, in addition to ordering “off-the-shelf” cell culture media. Access to these platforms will accelerate the development of cellular therapies by making custom cell media available early during process development and simplifying downstream scale up. [Read more…]
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- …
- 117
- Next Page »